Table 1.
Baseline clinical characteristics, choice of treatment, and adverse events of patients with EGFR-WT and EGFR-mutant NSCLC
| Variable | Total population (N = 28) |
EGFR-WT (N = 13) |
EGFR-mutant (N = 15) |
P |
|---|---|---|---|---|
| Sex, no. (%) | 0.13 | |||
| • Male | 14 (50) | 4 (30.7) | 10 (66.6) | |
| • Female | 14 (50) | 9 (69.2) | 5 (33.3) | |
| Age (years) | 0.77 | |||
| • Mean ± SD | 63.6 ± 8.8 | 63.0 ± 9.7 | 64.0 ± 8.2 | |
| BW (kg) | 0.28 | |||
| • Median | 50.3 | 50.7 | 50 | |
| • Range | 42—76 | 45—76 | (42—76) | |
| BMI (kg/m2), no. (%) | 0.43 | |||
| • Underweight (<18.5) | 3 (10.7) | 0 (0) | 3 (20.0) | |
| • Normal (18.5–22.9) | 13 (46.4) | 6 (46.1) | 7 (46.6) | |
| • Overweight (23–24.9) | 6 (21.4) | 4 (30.7) | 2 (13.3) | |
| • Obese (> 25) | 6 (21.4) | 3 (23.0) | 3 (20.0) | |
| WHO performance status (ECOG), no. (%) | 0.69 | |||
| • 0 | 7 (25.0) | 2 (15.3) | 5 (33.3) | |
| • 1 | 19 (67.8) | 10 (76.9) | 9 (60.0) | |
| • 2 | 2 (7.1) | 1 (7.6) | 1 (6.6) | |
| Smoking status, no. (%) | 0.48 | |||
| • Never-smoker | 20 (71.4) | 10 (76.9) | 10 (66.6) | |
| • Ex-smoker | 5 (17.8) | 1 (7.6) | 4 (26.6) | |
| • Current smoker | 3 (10.7) | 2 (15.3) | 1 (6.67) | |
| Underlying disease, no. (%) | ||||
| • Diabetes mellitus | 5 (17.8) | 3 (23.0) | 2 (13.3) | 0.64 |
| • Hypertension | 12 (42.8) | 6 (46.1) | 6 (40.0) | 0.74 |
| • Dyslipidemia | 7 (25.0) | 1 (7.6) | 6 (40.0) | 0.08 |
| • Chronic obstructive pulmonary disease | 0 (0) | 0 (0) | 0 (0) | |
| • Inflammatory bowel disease | 0 (0) | 0 (0) | 0 (0) | |
| Previous GI tract surgery, no. (%) | 1 (3.5) | 0 (0) | 1 (6.6) | > 0.99 |
| Drug use in past 4 weeks, no. (%) | ||||
| • Antibiotics | 3 (10.7) | 2 (15.3) | 1 (6.6) | 0.58 |
| • Proton pump inhibitors | 5 (17.8) | 1 (7.6) | 4 (26.6) | 0.33 |
| • Laxatives | 8 (28.5) | 4 (30.7) | 4 (26.6) | > 0.99 |
| • Prebiotics/probiotics | 8 (28.5) | 3 (23.0) | 5 (33.3) | 0.69 |
| • Supplement | 4 (14.2) | 2 (15.3) | 2 (13.3) | 0.78 |
|
Non-small cell lung cancer Histologic subtype, no. (%) |
0.21 | |||
| • Adenocarcinoma | 25 (85.2) | 11 (84.6) | 14 (93.3) | |
| • Squamous cell carcinoma | 2 (7.1) | 2 (15.3) | 0 (0) | |
| • Adenosquamous cell carcinoma | 1 (3.5) | 0 (0) | 1 (6.67) | |
| Stage at diagnosis, no. (%) | 0.82 | |||
| • IIIb | 1 (3.5) | 0 (0) | 1 (6.6) | |
| • IIIc | 2 (7.1) | 1 (7.6) | 1 (6.6) | |
| • IVa | 19 (67.8) | 10 (76.9) | 9 (60.0) | |
| • IVb | 6 (21.4) | 2 (15.3) | 4 (26.6) | |
| Albumin (g/dL), no. (%) | 0.02 | |||
|
< 3.2 ≥ 3.2 |
12 (42.8) 16 (57.1) |
9 (69.2) 4 (30.7) |
3 (20.0) 12 (80) |
|
| EGFR status, no. (%) | ||||
| • Wild-type | 13 (100) | 0 (0) | ||
| • Exon 19 deletion | 8 (53.3) | |||
| • Exon 21 L858R | 5 (33.3) | |||
|
• Uncommon mutations (G719X, S768I, L861Q) |
2 (13.3) | |||
| Treatment regimen, no. (%) | ||||
| • Carboplatin/paclitaxel | 13 (100) | |||
| • Gefitinib | 4 (26.6) | |||
| • Erlotinib | 4 (26.6) | |||
| • Osimertinib | 2 (13.3) | |||
| • Others | 5 (33.3) | |||
| Adverse events, no. (%) | 0.66 | |||
|
Grade< 2 Grade≥ 2 |
12 (42.8) 16 (57.1) |
5 (38.4) 8 (61.5) |
7 (46.6) 8 (53.3) |
BMI Body mass index, BW Body weight, EGFR Epidermal growth factor receptor, GI Gastrointestinal, WHO World Health Organization